ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington's disease; and QRX-504 to treat Fuchs' endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRQR
CUSIPN/A
Phone31-88-166-7000
Debt
Debt-to-Equity Ratio0.19
Current Ratio5.64
Quick Ratio5.64
Price-To-Earnings
Trailing P/E Ratio-3.27
Forward P/E Ratio-4.28
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.39 per share
Price / Book4.71
Profitability
EPS (Most Recent Fiscal Year)($1.94)
Net Income$-49,320,000.00
Net MarginsN/A
Return on Equity-128.44%
Return on Assets-93.68%
Miscellaneous
Employees133
Outstanding Shares31,860,000
ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions
What is ProQR Therapeutics' stock symbol?
ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."
How were ProQR Therapeutics' earnings last quarter?
ProQR Therapeutics NV (NASDAQ:PRQR) issued its quarterly earnings data on Wednesday, May, 16th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.48) by $0.06. View ProQR Therapeutics' Earnings History.
When is ProQR Therapeutics' next earnings date?
What price target have analysts set for PRQR?
4 brokerages have issued twelve-month price objectives for ProQR Therapeutics' shares. Their predictions range from $4.50 to $40.00. On average, they anticipate ProQR Therapeutics' share price to reach $19.1250 in the next year. View Analyst Ratings for ProQR Therapeutics.
Who are some of ProQR Therapeutics' key competitors?
Some companies that are related to ProQR Therapeutics include AMAG Pharmaceuticals (AMAG), Theratechnologies (THERF), CymaBay Therapeutics (CBAY), NuCana (NCNA), ANI Pharmaceuticals Inc Common Stock (ANIP), Amphastar Pharmaceuticals (AMPH), Abeona Therapeutics (ABEO), Inflarx (IFRX), Urogen Pharma (URGN), Vectura Group (VEGPF), Geron (GERN), Homology Medicines (FIXX), Odonate Therapeutics (ODT), Arcus Biosciences (RCUS) and Adamas Pharmaceuticals (ADMS).
Who are ProQR Therapeutics' key executives?
ProQR Therapeutics' management team includes the folowing people:
- Mr. Daniel A. de Boer, Chief Exec. Officer and Member of Management Board (Age 35)
- Mr. Rene K. Beukema, Chief Corp. Devel. Officer, Gen. Counsel, Corp. Sec. & Member-Management Board (Age 54)
- Ms. Smital Shah, Chief Financial Officer (Age 42)
- Mr. Joost Clement, Director of HR
- Mr. Bart Klein, Sr. VP of Intellectual Property
Has ProQR Therapeutics been receiving favorable news coverage?
News headlines about PRQR stock have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ProQR Therapeutics earned a news sentiment score of 0.13 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.78 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are ProQR Therapeutics' major shareholders?
ProQR Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sphera Funds Management LTD. (2.07%), Sabby Management LLC (0.54%), Opus Point Partners Management LLC (0.48%) and JPMorgan Chase & Co. (0.10%). View Institutional Ownership Trends for ProQR Therapeutics.
Which major investors are selling ProQR Therapeutics stock?
Which major investors are buying ProQR Therapeutics stock?
How do I buy shares of ProQR Therapeutics?
Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ProQR Therapeutics' stock price today?
One share of PRQR stock can currently be purchased for approximately $6.55.
How big of a company is ProQR Therapeutics?
ProQR Therapeutics has a market capitalization of $213.46 million. The biopharmaceutical company earns $-49,320,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. ProQR Therapeutics employs 133 workers across the globe.
How can I contact ProQR Therapeutics?
ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]
MarketBeat Community Rating for ProQR Therapeutics (PRQR)
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote "Outperform" if you believe PRQR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.
